Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics-based coumarin therapy.

Brian F Gage1

  • 1Washington University School of Medicine, St. Louis, MO 63110, USA. bgage@wustl.edu

Hematology. American Society of Hematology. Education Program
|November 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-to-start of anticoagulant therapy and mortality in pulmonary embolism.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Risk factors for anticoagulant-related bleeding in cancer: traditional and cancer-specific factors.

Blood vessels, thrombosis & hemostasis·2025
Same author

Association of anticoagulant therapy with bleeding in patients with chronic liver disease: A case-cross over study using the National Veterans Health Administration database.

Thrombosis research·2025
Same author

A Combined Intravenous and Oral Metoprolol Regimen to Reduce Perioperative Myocardial Injury: The ORION Trial.

Anesthesia and analgesia·2025
Same author

Catheter and Surgical Ablation for Atrial Fibrillation : A Systematic Review and Meta-analysis.

Annals of internal medicine·2025
Same author

Association between anticoagulant-related bleeding and mortality in patients with hematological malignancies and cancer-associated venous thromboembolism.

Thrombosis research·2025
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Pharmacogenetics helps estimate the correct coumarin dose, reducing hemorrhage risk. Genotyping for single nucleotide polymorphisms (SNPs) in CYP2C9 and VKORC1 allows personalized dosing for safer and more effective coumarin therapy.

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Genetics

Background:

  • Coumarin therapy requires accurate initial dosing to prevent hemorrhage.
  • Current methods lack precision in estimating therapeutic coumarin doses.
  • Individual variability in coumarin response necessitates personalized treatment approaches.

Purpose of the Study:

  • To introduce pharmacogenetics-based therapy for estimating coumarin dosage.
  • To improve the safety and effectiveness of coumarin treatment.
  • To utilize genetic information for personalized coumarin dose selection.

Main Methods:

  • Genotyping patients for single nucleotide polymorphisms (SNPs) affecting coumarin metabolism and sensitivity.
  • Analyzing SNPs in cytochrome P450 complex (CYP2C9) for metabolic rate.

Related Experiment Videos

  • Assessing VKORC1 promoter polymorphisms for coumarin sensitivity.

    • Main Results:

    • CYP2C9 variants (CYP2C9*2, CYP2C9*3) indicate slower metabolism, requiring reduced initial doses.
    • VKORC1 promoter polymorphism (-1639 G>A) correlates with increased coumarin sensitivity, necessitating lower starting doses.
    • Pharmacogenetic profiling enables estimation of appropriate therapeutic coumarin doses.

    Conclusions:

    • Pharmacogenetics-based coumarin therapy offers a method to estimate optimal initial doses.
    • Personalized dosing based on CYP2C9 and VKORC1 genotypes can enhance coumarin therapy safety.
    • This approach may lead to improved clinical outcomes in patients receiving coumarin treatment.